KR101855395B1 - Screening method of lung tumor using near-infrared light - Google Patents
Screening method of lung tumor using near-infrared light Download PDFInfo
- Publication number
- KR101855395B1 KR101855395B1 KR1020160123392A KR20160123392A KR101855395B1 KR 101855395 B1 KR101855395 B1 KR 101855395B1 KR 1020160123392 A KR1020160123392 A KR 1020160123392A KR 20160123392 A KR20160123392 A KR 20160123392A KR 101855395 B1 KR101855395 B1 KR 101855395B1
- Authority
- KR
- South Korea
- Prior art keywords
- infrared rays
- chest wall
- tumor
- near infrared
- present
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000012216 screening Methods 0.000 title claims abstract description 31
- 208000037841 lung tumor Diseases 0.000 title claims abstract description 26
- 208000020816 lung neoplasm Diseases 0.000 title claims description 18
- 206010072960 Chest wall tumour Diseases 0.000 claims abstract description 45
- 208000018223 neoplasm of chest wall Diseases 0.000 claims abstract description 45
- 210000000779 thoracic wall Anatomy 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000007850 fluorescent dye Substances 0.000 claims description 14
- 210000004204 blood vessel Anatomy 0.000 claims description 10
- 239000013307 optical fiber Substances 0.000 claims description 10
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical group [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 9
- 229960004657 indocyanine green Drugs 0.000 claims description 9
- 238000003384 imaging method Methods 0.000 claims description 8
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 230000005284 excitation Effects 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000013399 early diagnosis Methods 0.000 abstract description 7
- 208000006178 malignant mesothelioma Diseases 0.000 abstract description 7
- 206010063599 Exposure to chemical pollution Diseases 0.000 abstract description 2
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 230000003211 malignant effect Effects 0.000 abstract description 2
- 210000004224 pleura Anatomy 0.000 description 12
- 238000010171 animal model Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000010425 asbestos Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229910052895 riebeckite Inorganic materials 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- 206010035600 Pleural fibrosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
The present invention relates to a method of screening lung tumors using near-infrared rays, comprising the steps of projecting the near-infrared rays irradiated to the location of the chest wall tumor through the chest wall and extrapolating from the body to the outside, and detecting this to image the shade of the chest wall tumor In order to early diagnose malignant hereditary species as a chest wall tumor, it is necessary to periodically screen for a high-risk group having asbestos exposure power. The diagnostic method according to the present invention enables early diagnosis of malignant mesothelioma .
Description
More particularly, the present invention relates to a method for screening lung tumors using near infrared rays. More particularly, the present invention relates to a method for screening lung tumors using near infrared rays. More specifically, near infrared rays or near infrared rays irradiated to chest wall tumors are projected through a chest wall, Or by imaging with a camera in conjunction with a fluorescent dye injected through a blood vessel, or by imaging with a spectroscope through the difference in the absorbance of multiple wavelengths of near-infrared light to determine the presence and extent of chest wall tumors And to a lung tumor screening method using near-infrared rays.
Asbestos classified as a primary carcinogen in the International Agency for Research on Cancer (WHO / IARC) under the World Health Organization is one of the leading causes of malignant mesothelioma, a pulmonary tumor that occurs in the pleura. It has a latency period of 15 to 40 years.
On the other hand, as shown in FIG. 1, the pleura consists of a parietal pleura and a visceral pleura. Pleural plaques occurring in the pleura are also caused by exposure to asbestos. However, because these tuberculosis is also caused by tuberculosis, there is a lack of reason for asbestos-related compensation because of the high prevalence of tuberculosis in Korea and lack of evidence on the clinical symptoms of pleura.
In addition, malignant mesothelioma has poor prognosis (less than 1 year survival rate after diagnosis), and incidence and mortality rate are continuously increasing. This is because early diagnosis is very difficult.
The current X-ray chest examination usually requires the size of the cancer to be 5 to 10 mm or more to identify the abnormal region. It is protected by the ribs, and the lung is overlapped with the position of the heart. There are many limitations that can not be achieved. In addition, even if the abnormality is confirmed by X-ray chest examination, the lung tissue is in direct contact with the air and is closely connected with the blood vessel, so that it is highly likely that the lung is already metastasized. Therefore, X-ray chest examination is very ineffective as an early diagnostic method for lung tumors.
Especially, as shown in Fig. 2, malignant mesothelioma that occurs in the thin pleura or peritoneum is not helpful for early diagnosis because of insufficient resolution of computed tomography or PET-CT.
On the other hand, there have been studies on cancer biomarkers in blood for early diagnosis, but it is difficult to overcome nonspecificity and improvement of diagnosis rate is not done well. As shown in FIG. 2, studies on minimally invasive malignant mesothelioma using these techniques have been conducted on animals. However, since they are invasive methods, they are limited to be used for early diagnosis.
SUMMARY OF THE INVENTION The present invention has been made in order to solve all of the above problems, and it is an object of the present invention to provide a method and apparatus for detecting near-infrared rays irradiated up to the position of a chest wall tumor of a pleura through a chest wall, The present invention provides a method for screening lung tumors using near-infrared rays, in which the presence or absence and extent of chest wall tumors are confirmed.
Another objective is to detect the neovascularization of the chest wall tumors when the fluorescent dye emits fluorescence from the chest wall tumor by the fluorescent dye, which is irradiated to the chest wall tumor site when the fluorescent dye is deposited in the chest wall tumor by injecting the fluorescent dye into the blood vessel And a method for screening lung tumors using near-infrared rays to confirm the presence or absence of chest wall tumors.
Another goal was to measure the intensity of light from multiple near-infrared rays of different wavelengths simultaneously or sequentially to the chest wall tumors of the pleura and to measure the intensity of the light by using near- Thereby providing a tumor screening method.
In order to achieve the above object, the present invention provides a method for screening lung tumors using near-infrared rays, comprising: projecting near-infrared rays irradiated to a chest wall tumor through a chest wall through a body; And imaging the shadow of the tumor.
In addition, it is preferable that the near-infrared ray camera irradiates the near-infrared rays through the optical fiber inserted to the position of the chest wall tumor in the projection of the near-infrared rays, and detects the near-infrared rays in the projection.
In addition, it is preferable to insert the optical fiber into the guide sheath, further comprising inserting the guide sheath into the working channel of the bronchoscope to the position of the chest wall tumor before the irradiation of the near infrared rays after the insertion of the optical fiber.
Further, the near-infrared rays are preferably near-infrared rays in the wavelength region of 780 to 2000 nm.
Further, it is preferable that the method further comprises a step of injecting a fluorescent dye into a blood vessel prior to the step of irradiating near-infrared rays, wherein the fluorescent dye leaks from immature blood vessels around the chest wall tumors and is deposited on the wall tumor, , Which is characterized by the imaging of new blood vessels of chest wall tumors that emit fluorescence.
The fluorescent dye is preferably indocyanine green (ICG).
And a radiation filter disposed on the front surface of the near-infrared ray detecting camera.
And an excitation filter disposed on the front surface of the near-infrared light source.
Further, the near-infrared rays are irradiated with near-infrared rays of a plurality of different wavelength ranges, and the intensity of light of each of the near-infrared rays passing through the chest wall is measured or imaged to confirm the presence or absence of a chest wall tumor through the difference in absorbency have.
In addition, it is preferable that the presence of the chest wall tumor is confirmed by the difference in absorbency by the spectroscope or the hyper-spectral camera.
According to the present invention, it is necessary to regularly screen a high-risk group having asbestos exposure power for early diagnosis of malignant hereditary species as a chest wall tumor. In the screening method according to the present invention, malignant mesothelioma It is possible to perform early diagnosis.
Figure 1 shows an anatomical image showing a pleura consisting of a parietal pleura and a visceral pleura.
Figure 2 shows normal findings on PET / CT. However, PET / CT and endoscopic photographs (Roca E, Laroumagne S, Vandemoortele T, Berdah S, Dutau H, Maldonado F , Astoul P., "18F-fluoro-2-deoxy-d-glucose positron emission tomography / computed tomography fused imaging in malignant mesothelioma patients: Lung cancer" 2013 Feb; 79 (2): 187 -90. Doi: 10.1016 / j.lungcan.2012.10.017. Epub 2012 Dec 1.)
FIG. 3 is a conceptual diagram showing a lung tumor screening method using near-infrared rays according to the first embodiment of the present invention
4 is an enlarged view of the main part of Fig. 3
5 is a conceptual diagram showing a lung tumor screening method using near-infrared rays according to a second embodiment of the present invention
6 is a conceptual diagram showing a lung tumor screening method using near-infrared rays according to a third embodiment of the present invention
FIG. 7 shows an example of applying a lung tumor screening method using near-infrared rays to an animal model according to the present invention
8 is an image showing an example of a normal chest wall by applying a lung tumor screening method using near-infrared rays according to the present invention to an animal model
9 is an image showing an example of a chest wall tumor by applying a lung tumor screening method using near-infrared rays according to the present invention to an animal model
Hereinafter, preferred embodiments of a lung tumor screening method using near-infrared rays according to the present invention will be described in detail with reference to the accompanying drawings. It is to be understood that the present invention is not limited to the disclosed embodiments, but may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, It is provided to inform.
FIG. 3 is a conceptual view showing a lung tumor screening method using near-infrared rays according to the first embodiment of the present invention, and FIG. 4 is an enlarged view of the main part of FIG.
The near-infrared ray lung tumor screening method according to the first embodiment of the present invention proposes a method of acquiring an image of a chest wall tumor using a projection method using near-infrared rays to simply diagnose screening of chest wall tumors. Near-infrared rays are electromagnetic waves having wavelengths in the range of 780 to 2000 nm, and have high permeability in tissues and are often used for biomedical diagnosis.
As shown in FIG. 3, the NIR source is irradiated to the site of the chest wall tumor. When the irradiated near-infrared ray is projected from the body through the chest wall and projected, , And the near infrared ray that has passed through the chest wall is detected and imaged by a near infrared ray camera located outside the body. At this time, the shade of the chest wall tumor in the near-infrared ray-detected image is acquired by the near-infrared ray detecting camera, so that the presence and spread of the chest wall tumor can be known.
As shown in FIG. 4, the guide sheath is inserted into a working channel of an endoscope, and the projection of the portion having the chest wall tumor is inserted into the working channel of the endoscope, The optical fiber is inserted into the guide sheath, and the near infrared rays are irradiated through the optical fiber to the site of the chest wall tumor and projected through the chest wall to the outside of the body. The near-infrared rays passing through the chest wall are checked for the presence and spread of chest wall tumors through the above-described process.
FIG. 5 is a conceptual diagram showing a lung tumor screening method using near-infrared rays according to a second embodiment of the present invention.
The method for screening lung tumors using near infrared rays according to the second embodiment of the present invention is a method of using fluorescence imaging using fluorescent dye Indocyanine green (ICG) that emits fluorescence by near infrared rays. Indocyanine green (ICG) binds readily to plasma proteins and is commonly used in vascular imaging, and has the property of absorbing maximum 780 nm light and emitting 820 nm fluorescence.
As shown in FIG. 5, when the chest wall tumor progresses, neovascularization occurs around the tumor. In such a case, a fluorescent dye such as ICG is injected into the blood vessel and the fluorescent dye leaking from the immature blood vessel around the chest wall tumor The neovascularization of a chest wall tumor which emits fluorescence by the near-infrared rays passing through the body in the body after being irradiated to the position of the chest wall tumor as described above is imaged by a near-infrared ray detection camera, The presence or absence of the tumor and the extent of spread. At this time, in order to image fluorescence emitted from the chest wall tumor, an 820 nm emission filter is arranged on the front face of the near-infrared ray camera and an excitation filter of 780 nm is arranged on the front face of the near-infrared light source.
In the second embodiment of the present invention, irradiation of the near-infrared rays is performed by the optical fiber as described above, and the optical fiber is inserted into the guide sheath of the working channel to position the chest wall tumor.
FIG. 6 is a conceptual diagram illustrating a lung tumor screening method using near-infrared rays according to a third embodiment of the present invention.
6, a method for screening lung tumors using near-infrared rays according to a third embodiment of the present invention includes the steps of simultaneously or sequentially applying two different wavelengths of a near-infrared ray band or a multi-wavelength NIR source of a plurality of wavelengths, The present invention proposes a near-infrared spectroscopy method for confirming the presence or absence of a tumor by measuring the intensity of near-infrared light passing through the chest wall in vitro, and measuring the intensity of the near-infrared light passing through the body. At this time, the intensity of the near-infrared light is measured or imaged to obtain a difference in absorbance by a near-infrared ray detector such as a spectroscope or a hyperspectral camera located outside the body.
FIG. 7 is an image showing an example in which near infrared rays are projected through a chest wall and extruded in vitro from the body by an endoscopic method, using a near-infrared ray lung-based screening method according to the present invention.
As shown in FIG. 7, the result is an image showing the chest wall near-infrared projection method using the near-infrared ray lung screening method of the first embodiment using the normal New Zealand white rabbit as the experimental animal as the animal model. In this image, it can be seen that a considerable amount of near-infrared rays are projected through the chest wall and projected to the outside in the red visible portion.
FIG. 8 is an image showing near infrared rays projected through the normal chest wall of New Zealand white rabbit; and FIG. 9 is an image showing near infrared rays projected through the tumor chest wall.
As can be seen from FIGS. 8 and 9, the normal chest wall projection image shows shadows parallel to the sternum but the tumor chest wall projection image is darker as the tumor shade is added.
As described above, the method for screening pulmonary tumor using near-infrared rays according to the present invention has been described with reference to the drawings. However, the present invention is not limited to the embodiments and drawings disclosed in the present specification, It is needless to say that various modifications can be made by those skilled in the art within the scope of the present invention.
Claims (9)
Wherein the near infrared rays are irradiated through an optical fiber inserted to the position of the chest wall tumor in the projecting step of the near infrared rays and the near infrared rays are detected by the near infrared ray camera in the step of detecting the near infrared rays projected into the projection, Way.
Further comprising the step of inserting the guide sheath into the working channel of the bronchoscope to the position of the chest wall tumor before the irradiation of the near infrared rays after the insertion of the optical fiber, wherein the optical fiber is inserted into the guide sheath Lung tumor screening method.
Wherein the near-infrared rays are near-infrared rays in a wavelength range of 780 to 2000 nm.
The method of claim 1, further comprising injecting a fluorescent dye into a blood vessel prior to the step of irradiating near infrared rays, wherein the fluorescent dye leaks from immature blood vessels around the chest wall tumor and is deposited on the chest wall tumor, A method for screening pulmonary tumors using near-infrared light, characterized by imaging neovascularization of a chest wall tumor releasing.
Wherein the fluorescent dye is indocyanine green (ICG).
Further comprising a radiation filter disposed on a front surface of the near-infrared ray detecting camera and an excitation filter disposed on a front surface of the near-infrared ray light source.
Wherein the near-infrared rays are irradiated with near-infrared rays of a plurality of different wavelength ranges, and the intensity of light of each of the near-infrared rays passing through the chest wall is measured or imaged to confirm presence or absence of chest wall tumors through a difference in absorption degree. Lung tumor screening method.
Wherein the presence or absence of the chest wall tumor is confirmed by the difference in absorbency by the spectroscope.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160123392A KR101855395B1 (en) | 2016-09-26 | 2016-09-26 | Screening method of lung tumor using near-infrared light |
| PCT/KR2017/008771 WO2018056574A1 (en) | 2016-09-26 | 2017-08-11 | Pulmonary tumor screening method using near infrared rays |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160123392A KR101855395B1 (en) | 2016-09-26 | 2016-09-26 | Screening method of lung tumor using near-infrared light |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180033878A KR20180033878A (en) | 2018-04-04 |
| KR101855395B1 true KR101855395B1 (en) | 2018-05-09 |
Family
ID=61690475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160123392A KR101855395B1 (en) | 2016-09-26 | 2016-09-26 | Screening method of lung tumor using near-infrared light |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101855395B1 (en) |
| WO (1) | WO2018056574A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101460908B1 (en) | 2013-08-09 | 2014-11-17 | 서울여자대학교 산학협력단 | Lung tumor tracking system and the method in 4D CT images |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4445065A1 (en) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Methods for in-vivo diagnostics using NIR radiation |
| WO2007016048A2 (en) * | 2005-07-27 | 2007-02-08 | University Of Massachusetts Lowell | Infrared scanner for biological applications |
| CA2784576C (en) * | 2009-12-15 | 2020-01-07 | Shuming Nie | System and methods for providing real-time anatomical guidance in a diagnostic or therapeutic procedure |
| US20130211246A1 (en) * | 2011-12-27 | 2013-08-15 | Vinod PARASHER | METHODS AND DEVICES FOR GASTROINTESTINAL SURGICAL PROCEDURES USING NEAR INFRARED (nIR) IMAGING TECHNIQUES |
| US10517483B2 (en) * | 2012-12-05 | 2019-12-31 | Accuvein, Inc. | System for detecting fluorescence and projecting a representative image |
-
2016
- 2016-09-26 KR KR1020160123392A patent/KR101855395B1/en active IP Right Grant
-
2017
- 2017-08-11 WO PCT/KR2017/008771 patent/WO2018056574A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101460908B1 (en) | 2013-08-09 | 2014-11-17 | 서울여자대학교 산학협력단 | Lung tumor tracking system and the method in 4D CT images |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018056574A1 (en) | 2018-03-29 |
| KR20180033878A (en) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10314490B2 (en) | Method and device for multi-spectral photonic imaging | |
| EP1824379B1 (en) | System and method for normalized fluorescence or bioluminescence imaging | |
| CA2373299C (en) | Laser imaging apparatus using biomedical markers that bind to cancer cells | |
| WO2019148268A1 (en) | Devices, systems, and methods for tumor visualization and removal | |
| JP5406205B2 (en) | Method for detecting the presence of heterogeneity inside a turbid medium and apparatus for imaging the inside of a turbid medium | |
| US10244999B2 (en) | Three-dimensional image generating method and system using multi-energy X-ray image and optical image | |
| US9867599B2 (en) | Optical guided vacuum assisted biopsy device | |
| US10413619B2 (en) | Imaging device | |
| KR101710902B1 (en) | An astral lamp and astral lamp system about projection for near infrared fluoresence diagnosis | |
| KR101855395B1 (en) | Screening method of lung tumor using near-infrared light | |
| Boykoff et al. | Current clinical applications of Cerenkov luminescence for intraoperative molecular imaging | |
| Park et al. | Ultra-low-dose intraoperative X-ray imager for minimally invasive surgery: a pilot imaging study | |
| KR102392593B1 (en) | Multi-modal endoscopy system comprising radiation image | |
| KR101865657B1 (en) | Diagnostic apparatus for laryngeal cancer detection | |
| US10605736B2 (en) | Optical pathology systems and methods | |
| Patel | Assessment of optical transmission and image contrast at infrared wavelengths using tissue simulating phantoms and biological tissues | |
| Koenig et al. | Validation of an XCT/fDOT System on Mice | |
| Kuo et al. | In vivo bioluminescence tomography using multi-spectral and multiple-perspective image data | |
| Conde et al. | Fiber-optic technologies for tissue diagnosis in cardiovascular and oncology applications | |
| Koenig et al. | Research Article Validation of an XCT/fDOT System on Mice | |
| Ishizumi et al. | The Utilization of Autofluorescence in Flexible Bronchoscopy | |
| Yokoyama et al. | Conference 9316: Multimodal Biomedical Imaging X | |
| WO2009122342A1 (en) | Method and device for visualizing accumulation or depletion of a contrast agent in a turbid medium | |
| WO2009077953A1 (en) | Method for reconstructing an image of an interior of a turbid medium and device for imaging the interior of turbid media |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |